Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2013-10-17
Last Posted Date
2018-05-23
Lead Sponsor
Pejman Ghanouni
Target Recruit Count
5
Registration Number
NCT01965002
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Phase 4
Completed
Conditions
Interventions
First Posted Date
2013-09-10
Last Posted Date
2023-11-15
Lead Sponsor
Population Health Research Institute
Target Recruit Count
4012
Registration Number
NCT01938248
Locations
🇺🇸

Cardiovascular Associates of Mesa, PC, Mesa, Arizona, United States

🇺🇸

St. Vincent Heart Clinic, Little Rock, Arkansas, United States

🇺🇸

Langhorne Cardiology Consultants, Inc., Pensacola, Florida, United States

and more 126 locations

Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery

First Posted Date
2013-09-06
Last Posted Date
2019-08-05
Lead Sponsor
Fudan University
Target Recruit Count
112
Registration Number
NCT01936233
Locations
🇨🇳

Liver Cancer Institute, Shanghai, Shanghai, China

Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease

First Posted Date
2013-08-30
Last Posted Date
2019-08-08
Lead Sponsor
Inha University Hospital
Target Recruit Count
255
Registration Number
NCT01932203
Locations
🇰🇷

Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong-si, Gyeonggi-do, Korea, Republic of

🇰🇷

Hallym University Medical Center, Anyang, Korea, Republic of

🇰🇷

Eulji University School of Medicine, Daejeon, Korea, Republic of

and more 16 locations

Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events

First Posted Date
2013-08-16
Last Posted Date
2013-08-16
Lead Sponsor
Xijing Hospital
Target Recruit Count
3700
Registration Number
NCT01923818
Locations
🇨🇳

Xijing Hospital, Xi'an, Shaanxi, China

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events

First Posted Date
2013-08-16
Last Posted Date
2013-08-16
Lead Sponsor
Xijing Hospital
Target Recruit Count
10000
Registration Number
NCT01924325
Locations
🇨🇳

Xijing Hospital, Xi'an, Shaanxi, China

Aspirin, Heparin and Miscarriage

First Posted Date
2013-08-07
Last Posted Date
2013-08-07
Lead Sponsor
University of Khartoum
Target Recruit Count
150
Registration Number
NCT01917799
Locations
🇱🇾

Misurata Teaching Hospital, Misurata, Libyan Arab Jamahiriya

Multiple Daily Doses of Aspirin to Overcome Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)- Part B

First Posted Date
2013-07-18
Last Posted Date
2015-03-19
Lead Sponsor
Hamilton Health Sciences Corporation
Target Recruit Count
70
Registration Number
NCT01902498
Locations
🇨🇦

Hamilton General Hospital, Hamilton, Ontario, Canada

Pharmacogenomics of Antiplatelet Response - II (PARes-II)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2013-07-10
Last Posted Date
2017-01-09
Lead Sponsor
Johns Hopkins University
Target Recruit Count
33
Registration Number
NCT01894555
Locations
🇺🇸

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Low Dose Aspirin for the Prevention of Preeclampsia

Phase 3
Conditions
Interventions
First Posted Date
2013-07-01
Last Posted Date
2013-07-01
Lead Sponsor
Saint Thomas Hospital, Panama
Target Recruit Count
476
Registration Number
NCT01890005
Locations
🇵🇦

Saint Thomas Maternity Hospital, Panama, Panama

© Copyright 2024. All Rights Reserved by MedPath